Quality of life among borderline ovarian tumor survivors: A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study.
Babette van der EerdenBelle H de RooijLeo J SchoutenDorry BollDennis van HamontM Caroline VosNicole P M EzendamPublished in: Gynecologic oncology (2024)
In general, BOT survivors' HRQoL lies between the HRQoL of early-stage ovarian cancer survivors and of the cancer-free population, but clinical effect sizes between the groups were mostly only trivial.